Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Optimizing Survival in Advanced Prostate Cancer: Conclusion

Share :

ESMO 2014

26 - 30 Sep 2014
Sorry, this item is currently unavailable.
Published: 29 Jan 2015
Views: 3863
Rating:
Save
Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium

Dr Tombal concludes the session which looked at treatment choices in prostate cancer.

From the same symposium:

Welcome and introduction

Understanding PC heterogeneity to guide treatment choices

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

CHAARTED: What are the implications for the future?

Learnings from real life practice

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
Multiple myeloma in a resource constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
Erdafitinib and current treatment landscape for advanced bladder cancer
Dr Yohann Loriot and Prof Arlene Siefker-Radtke
Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )
5 Jun 2023
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022
An overview of treatment advances in gastric cancer
Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA
An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )
18 Aug 2022
Locally and advanced immunotherapy developments and new agents in lung cancer
Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA
Locally and advanced immunotherapy developments and new agents in lung cancer ( Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA )
9 Jul 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation